Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
https://www.youtube.com/watch?v=4MecjQHamEo&ab_channel=M%26SMoneyMoves … [Read more...] about An Intro to EMA’s When Trading Biotech Stocks
Introduction Conatus Pharmaceuticals (Nasdaq: CNAT) recently released highly anticipated top-line data from their Encore-PH clinical trial. The study investigated the efficacy and safety of … [Read more...] about A Closer Look At CNAT’s “Failed” Clinical Study
After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
MS Money Moves Swing thesis for AcelRX Pharma (ACRX) published last week in our "Swing Alert"article played out nicely. ACRX spiked ~70% from $2.90 to $4.92 in the last 5 trading sessions. The upward … [Read more...] about ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It